Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Lock

Showing results (181-190 of 220) with videos related to

Pageof 22
Sort By:
Journal of Molecular Medicine (Berlin, Germany)|February 13, 2024
FDA-approved disulfiram as a novel treatment for aggressive leukemiaMawar Karsa, Lin Xiao, Emma Ronca, et al.
British Journal of Haematology|June 5, 2026
BCL-2 and MCL1 co-inhibition enhances glucocorticoid therapy in preclinical models of infant KMT2A-rearranged acute lymphoblastic leukaemiaMawar Karsa, Ayu Karsa, Dayna Spurling, et al.
Blood|February 4, 2015
Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemiaShannon L Maude, Sibasish Dolai, Cristina Delgado-Martin, et al.
Leukemia|October 17, 2020
Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemiaHeather C Murray, Anoop K Enjeti, Richard G S Kahl, et al.
Oncotarget|June 23, 2016
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitorsAmanda M Smith, Matthew D Dun, Erwin M Lee, et al.
Blood|July 22, 2010
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibitionPetra S Bachmann, Rocco G Piazza, Mary E Janes, et al.
Hemasphere|January 20, 2025
The CD123 antibody-drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemiaBen Watts, Christopher M Smith, Kathryn Evans, et al.
Molecular Cancer Therapeutics|December 16, 2014
Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemiaSanti Suryani, Lauryn S Bracken, Richard C Harvey, et al.
Cancer Discovery|August 21, 2021
PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by <i>NSD2</i> Mutation in Pediatric Acute Lymphoblastic LeukemiaJianping Li, Julia Hlavka-Zhang, Jonathan H Shrimp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2014
Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenograftsSanti Suryani, Hernan Carol, Triona Ni Chonghaile, et al.
Pageof 22

Showing results (181-190 of 220) with videos related to

Sort By:
Pageof 22
Journal of Molecular Medicine (Berlin, Germany)|February 13, 2024
FDA-approved disulfiram as a novel treatment for aggressive leukemiaMawar Karsa, Lin Xiao, Emma Ronca, et al.
British Journal of Haematology|June 5, 2026
BCL-2 and MCL1 co-inhibition enhances glucocorticoid therapy in preclinical models of infant KMT2A-rearranged acute lymphoblastic leukaemiaMawar Karsa, Ayu Karsa, Dayna Spurling, et al.
Blood|February 4, 2015
Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemiaShannon L Maude, Sibasish Dolai, Cristina Delgado-Martin, et al.
Leukemia|October 17, 2020
Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemiaHeather C Murray, Anoop K Enjeti, Richard G S Kahl, et al.
Oncotarget|June 23, 2016
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitorsAmanda M Smith, Matthew D Dun, Erwin M Lee, et al.
Blood|July 22, 2010
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibitionPetra S Bachmann, Rocco G Piazza, Mary E Janes, et al.
Hemasphere|January 20, 2025
The CD123 antibody-drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemiaBen Watts, Christopher M Smith, Kathryn Evans, et al.
Molecular Cancer Therapeutics|December 16, 2014
Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemiaSanti Suryani, Lauryn S Bracken, Richard C Harvey, et al.
Cancer Discovery|August 21, 2021
PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by <i>NSD2</i> Mutation in Pediatric Acute Lymphoblastic LeukemiaJianping Li, Julia Hlavka-Zhang, Jonathan H Shrimp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2014
Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenograftsSanti Suryani, Hernan Carol, Triona Ni Chonghaile, et al.
Pageof 22